Centaur Pharma’s API Ambernath Facility Receives EIR from the USFDA


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Centaur Pharmaceuticals’ state-of-the-art API Ambernath facility was audited by the USFDA and a 483 form was issued with one observation

Centaur Pharmaceuticals’ state-of-the-art API Ambernath facility was audited by the USFDA and a 483 form was issued with one observation which was responded to, immediately. Centaur has now received a formal EIR (Establishment Inspection Report) from USFDA stating the facility is cGMP compliant and the audit outcome is categorized as VAI (Voluntary Action Indicated). This is the fifth successive GMP certification for the Centaur Ambernath API facility by the USFDA in a span of 11 years.

 

In addition to the USFDA accreditation, the Ambernath facility conforms to EUGMP/ANSM (France), TGA, PMDA (Japan), KFDA (Korea), ANVISA (Brazil), COFEPRIS (Mexico) and WHO-GMP standards. Centaur is India’s largest, and the world’s third largest manufacturer of psychotropic API. Centaur manufactures over 50 API, of which 32 have been introduced for the first time in India.

 

Mr. S.D. Sawant, Managing Director, Centaur Pharmaceuticals said, “Centaur Pharma has been diligently complying with GMP regulations to work towards zero observations in USFDA inspections. We have faced over fifteen audits by the USFDA in the past decade, for our various facilities and successfully cleared the same. This is a proud moment for Centaur, and a significant milestone for the Indian pharmaceutical industry.”

 

Earlier in May 2019, Centaur Pharmaceuticals oral solid dosage facility in Pune had received no action indicated (NAI) compliance status, with zero 483 observations from the USFDA. In addition to the USFDA accreditation, the Pune facility also conforms to MHRA (UK), TGA (Australia), Health Canada, MCC (South Africa) and WHO-GMP standards. In September 2019 LifeSan, the clinical research division of Centaur Pharmaceuticals was audited by the US FDA and was concluded with zero 483 observations.

 

Centaur Pharmaceuticals is a US$ 100 million Indian pharmaceutical company with exports to 110 countries. Centaur has presence across the pharmaceutical value chain with proficiency in API, formulations, clinical research and contract manufacturing. Centaur is ranked 35th in India by prescriptions and markets Sinarest the leader in the anticold prescription market for over two decades.

 

Tags : #centaurpharmas #france #japan #korea #brazil #mexico #india #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026